New pathways of the renin-angiotensin system: The role of ACE2 in cardiovascular pathophysiology and therapy

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 5, 2010, Pages 485-496

  Castro Chaves, Paulo ^a   Cerqueira, Rui ^a   Pintalhao, Mariana ^a   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

Author keywords

Angiotensin 1 7; Angiotensin converting enzyme 2; Atherosclerosis; Fibrosis; Hypertension; Hypertrophy; Mas receptor; Myocardial ischemia; Vasodilation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LENTIVIRUS VECTOR; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE;

ABSENCE OF SIDE EFFECTS; AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LUNG CANCER; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR FIBROSIS;

CARDIOVASCULAR DISEASES; HUMANS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 77951101164     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003709784     Document Type: Review

References (112)

1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34
2. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472
3. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006;7:3-14
4. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin--angiotensin systems. Physiol Rev 2006;86:747-803
5. Schiavone MT, Santos RA, Brosnihan KB, et al. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1 -- 7) heptapeptide. Proc Natl Acad Sci USA 1988;85:4095-4098
6. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1 -- 7)--Mas axis. Exp Physiol 2008;93:519-527
7. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1 -- 7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-90
8. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1 -- 7) on isolated rabbit afferent arterioles. Hypertension 2002;39:799-802
9. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1 -- 7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-8263
10. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1 -- 7). Cardiovasc Res 2007;73:463-469
11. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1 -- 9. Circ Res 2000;87:E1-9
12. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238-33243
13. Castro CH, Santos RA, Ferreira AJ, et al. Evidence for a functional interaction of the angiotensin-(1 -- 7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005;46:937-942
14. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-828
15. Zhang H, Wada J, Hida K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001;276:17132-17139
16. Akpinar P, Kuwajima S, Krutzfeldt J, Stoffel M. Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation. Cell Metab 2005;2:385-397
17. Danilczyk U, Sarao R, Remy C, et al. Essential role for collectrin in renal amino acid transport. Nature 2006;444:1088-1091
18. Camargo SM, Singer D, Makrides V, et al. Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. Gastroenterology 2009;136:872-882
19. Guy JL, Jackson RM, Acharya KR, et al. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003;42:13185-13192
20. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-14843
21. Guy JL, Lambert DW, Turner AJ, Porter KE. Functional angiotensin- converting enzyme 2 is expressed in human cardiac myofibroblasts. Exp Physiol 2008; 93:579-588
22. Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005;280:30113-30119
23. Shaltout HA, Westwood BM, Averill DB, et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 2007;292:F82-91
24. Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006;48:914-920
25. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006;48:572-578
26. Warner FJ, Lew RA, Smith AI, et al. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 2005;280:39353-39362
27. Lew RA, Warner FJ, Hanchapola I, et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008;93:685-693
28. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107-110
29. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005;26:369-75; discussion 22-24
30. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006;17:3067-3075
31. Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II Type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol 2009;296:F398-405
32. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637
33. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens 1990;8:715-724
34. Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004;383:45-51
35. Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1 -- 7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003;108:1707-1712
36. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1 -- 7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 2003;108:1679-1681
37. Gurley SB, Allred A, Le TH, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006;116:2218-2225
38. Yamada K, Iyer SN, Chappell MC, et al. Converting enzyme determines plasma clearance of angiotensin-(1 -- 7). Hypertension 1998;32:496-502
39. Mahon JM, Carr RD, Nicol AK, Henderson IW. Angiotensin(1 -- 7) is an antagonist at the Type 1 angiotensin II receptor. J Hypertens 1994;12:1377-1381
40. Rowe BP, Saylor DL, Speth RC, Absher DR. Angiotensin-(1 -- 7) binding at angiotensin II receptors in the rat brain. Regul Pept 1995;56:139-146
41. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1 -- 7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001;38:665-668
42. Tallant EA, Higson JT. Angiotensin II activates distinct signal transduction pathways in astrocytes isolated from neonatal rat brain. Glia 1997;19:333-342
43. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1 -- 7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996;27:523-528
44. Santos RA, Haibara AS, Campagnole-Santos MJ, et al. Characterization of a new selective antagonist for angiotensin-(1 -- 7), D-pro7-angiotensin-(1 -- 7). Hypertension 2003;41:737-743
45. Young D, Waitches G, Birchmeier C, et al. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 1986;45:711-719
46. Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II Type 1 receptor. Circulation 2005;111:1806-1813
47. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1 -- 7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-192
48. Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1 -- 7)/Mas signaling pathway in cardiomyocytes. Hypertension 2008;52:542-548
49. Giani JF, Gironacci MM, Munoz MC, et al. Angiotensin-(1 -- 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ Physiol 2007;293:H1154-63
50. Tallant EA, Lu X, Weiss RB, et al. Bovine aortic endothelial cells contain an angiotensin-(1 -- 7) receptor. Hypertension 1997;29:388-393
51. Rebas E, Zabczynska J, Lachowicz A. The effect of angiotensin 1 -- 7 on tyrosine kinases activity in rat anterior pituitary. Biochem Biophys Res Commun 2006;347:581-585
52. Santos RA, Ferreira AJ. Angiotensin-(1 -- 7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 2007;16:122-128
53. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1 -- 7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 1994;111:652-654
54. Santos RA, Ferreira AJ, Pinheiro SV, et al. Angiotensin-(1 -- 7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005;14:1019-1031
55. Pinheiro SV, Simoes e Silva AC, Sampaio WO, et al. Nonpeptide AVE 0991 is an angiotensin-(1 -- 7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490-496
56. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1 -- 7) inhibits vascular smooth muscle cell growth. Hypertension 1996;28:104-108
57. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1 -- 7). Hypertension 2003;42:574-579
58. Langeveld B, van Gilst WH, Tio RA, et al. Angiotensin-(1 -- 7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005;45:138-141
59. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1 -- 7) reduces smooth muscle growth after vascular injury. Hypertension 1999;33:207-211
60. Zeng W, Chen W, Leng X, et al. Chronic angiotensin-(1 -- 7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 2009;389:138-144
61. Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008;295:H1377-84
62. Castro-Chaves P, Pintalhao M, Fontes-Carvalho R, et al. Acute modulation of myocardial function by angiotensin 1 -- 7. Peptides 2009;30:1714-1719
63. Leite-Moreira AF, Castro-Chaves P, Pimentel-Nunes P, et al. Angiotensin II acutely decreases myocardial stiffness: a novel AT1, PKC and Na+/H+ exchanger-mediated effect. Br J Pharmacol 2006;147:690-697
64. Castro-Chaves P, Fontes-Carvalho R, Pintalhao M, et al. Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart. Exp Physiol 2009;94:665-674
65. Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1 -- 7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005;289:H2356-63
66. Santos RA, Ferreira AJ, Nadu AP, et al. Expression of an angiotensin-(1 -- 7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004;17:292-299
67. Donoghue M, Wakimoto H, Maguire CT, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003;35:1043-1053
68. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1 -- 7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006;290:H2417-23
69. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1 -- 7). Am J Physiol Heart Circ Physiol 2007;292:H736-42
70. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1 -- 7) in ischemic cardiomyopathy. Circulation 2003;108:2141-2146
71. Mercure C, Yogi A, Callera GE, et al. Angiotensin(1 -- 7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008;103:1319-1326
72. Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1 -- 7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002;105:1548-1550
73. Pendergrass KD, Averill DB, Ferrario CM, et al. Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2.Lewis rat. Am J Physiol Renal Physiol 2006;290:F1497-506
74. Magaldi AJ, Cesar KR, de Araujo M, et al. Angiotensin-(1 -- 7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch 2003;447:223-230
75. Garcia NH, Garvin JL. Angiotensin 1 -- 7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 1994;5:1133-1138
76. DelliPizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin(1 -- 7). Br J Pharmacol 1994;111:1-3
77. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1 -- 7): in vivo and in vitro studies. Am J Physiol 1996;270:F141-7
78. Joyner J, Neves LA, Stovall K, et al. Angiotensin-(1 -- 7) serves as an aquaretic by increasing water intake and diuresis in association with downregulation of aquaporin-1 during pregnancy in rats. Am J Physiol Regul Integr Comp Physiol 2008;294:R1073-80
79. Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1 -- 7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 2009; 75:1184-1193
80. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007;72:614-623
81. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006;168:1808-1820
82. Fujita H, Omori S, Ishikura K, et al. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 2004;286:F120-6
83. Gava E, Samad-Zadeh A, Zimpelmann J, et al. Angiotensin-(1 -- 7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 2009;24:1766-1773
84. Zimpelmann J, Burns KD. Angiotensin-(1 -- 7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 2009;296:F337-46
85. Pereira RM, Dos Santos RA, Teixeira MM, et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1 -- 7). J Hepatol 2007;46:674-681
86. Neves LA, Stovall K, Joyner J, et al. ACE2 and ANG-(1 -- 7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol 2008;294:R151-61
87. Menon J, Soto-Pantoja DR, Callahan MF, et al. Angiotensin-(1 -- 7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007;67:2809-2815
88. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007;50:112-119
89. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005;90:783-790
90. Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 2006;27:12-19
91. Yamazato M, Yamazato Y, Sun C, et al. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007;49:926-931
92. Rentzsch B, Todiras M, Iliescu R, et al. Transgenic angiotensin- converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008;52:967-973
93. Dong B, Zhang C, Feng JB, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:1270-1276
94. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246-253
95. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990;150:1175-1183
96. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921
97. Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. Circulation 1993;87:VI78-87 (Pubitemid 23164226)
98. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828
99. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1 -- 7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 2005;46:948-952
100. Collister JP, Hendel MD. The role of Ang (1 -- 7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 2003;4:176-179
101. Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1 -- 7) on the endothelium. Hypertension 2002;40:847-852
102. Lemos VS, Silva DM, Walther T, et al. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1 -- 7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 2005;46:274-279
103. Benter IF, Yousif MH, Anim JT, et al. Angiotensin-(1 -- 7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006;290:H684-91
104. Ferreira AJ, Jacoby BA, Araujo CA, et al. The nonpeptide angiotensin-(1 -- 7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292:H1113-9
105. Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1 -- 7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1 -- 7) analog. J Pharmacol Exp Ther 2009;328:849-854
106. Lula I, Denadai AL, Resende JM, et al. Study of angiotensin-(1 -- 7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007;28:2199-2210
107. Silva-Barcellos NM, Frezard F, Caligiorne S, Santos RA. Long-lasting cardiovascular effects of liposome-entrapped angiotensin-(1 -- 7) at the rostral ventrolateral medulla. Hypertension 2001;38:1266-1271
108. Huentelman MJ, Zubcevic J, Hernandez Prada JA, et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 2004;44:903-906
109. Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008;51:1312-1317
110. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-1054
111. Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1 -- 7 [A(1 -- 7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 2006;57:559-568
112. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1 -- 7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009;8:1676-1683